REVERSIBLE CARDIOPATHY AFTER ACCIDENTAL OVERDOSE OF MITOXANTRONE

被引:7
作者
HACHIMIIDRISSI, S
SCHOTS, R
DEWOLF, D
VANBELLE, SJP
OTTEN, J
机构
[1] VRIJE UNIV BRUSSELS,ACAD HOSP,DEPT HEMATOL,B-1090 BRUSSELS,BELGIUM
[2] VRIJE UNIV BRUSSELS,ACAD HOSP,DEPT MED ONCOL,B-1090 BRUSSELS,BELGIUM
关键词
CARDIAC TOXICITY; MITOXANTRONE OVERDOSE;
D O I
10.3109/08880019309016526
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mitoxantrone is an anthraquinone structurally related to the anthracycline drugs doxorubicin and daunorubicin. In animal tumor models, it was equally cytotoxic as but less cardiotoxic than the parent compounds. We here describe the clinical course of a 9-year old girl who inadvertently received 100 mg/m2 of mitoxantrone as a bolus injection. Hemoperfusion carried out twice with the-objective of increasing the drug clearance was totally inefficient. Severe but transient myelotoxicity was induced. Sequential echocardiograms demonstrated a reversible decrease of the shortening fraction of the left ventricle.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 16 条
  • [1] ALLEGRA JC, 1985, INVEST NEW DRUG, V3, P153
  • [2] BENJAMIN RS, 1985, ADV CHEMOTHERAPY CUR, P69
  • [3] BETRA VK, 1986, DRUG METAB RES, V17, P311
  • [4] EARLY ANTHRACYCLINE CARDIOTOXICITY
    BRISTOW, MR
    THOMPSON, PD
    MARTIN, RP
    MASON, JW
    BILLINGHAM, ME
    HARRISON, DC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1978, 65 (05) : 823 - 832
  • [5] CROSSLEY RJ, 1984, SEMIN ONCOL, V11, P54
  • [6] HENDERSON BM, 1982, CANCER TREAT REP, V66, P1139
  • [7] MITOXANTRONE INDUCED CONGESTIVE HEART-FAILURE IN PATIENTS PREVIOUSLY TREATED WITH ANTHRACYCLINES
    JANMOHAMMED, R
    MILLIGAN, DW
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1989, 71 (02) : 292 - 293
  • [8] LATE CARDIAC EFFECTS OF DOXORUBICIN THERAPY FOR ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD
    LIPSHULTZ, SE
    COLAN, SD
    GELBER, RD
    PEREZATAYDE, AR
    SALLAN, SE
    SANDERS, SP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) : 808 - 815
  • [9] POSNER LE, 1985, INVEST NEW DRUG, V3, P123
  • [10] PRATT CB, 1983, CANCER TREAT REP, V67, P85